CD274 and non-small cell lung carcinoma: A total of 106 patients with NSCLC treated with anti-PD-1 Ab (pembrolizumab or nivolumab) or anti-PD-L1 Ab (atezolizumab) were enrolled between March 2017 and February 2021 (Table 1).